These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22857752)

  • 1. Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?
    Karaolides T; Skolarikos A; Bourdoumis A; Konandreas A; Mygdalis V; Thanos A; Deliveliotis C
    Urology; 2012 Aug; 80(2):354-9. PubMed ID: 22857752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
    Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
    BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer--re-TURBT recurrence rates in a prospective, randomized study.
    Geavlete B; Jecu M; Multescu R; Georgescu D; Geavlete P
    Urology; 2010 Sep; 76(3):664-9. PubMed ID: 20627289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
    Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
    Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
    Hermann GG; Mogensen K; Carlsson S; Marcussen N; Duun S
    BJU Int; 2011 Oct; 108(8 Pt 2):E297-303. PubMed ID: 21414125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
    Filbeck T; Pichlmeier U; Knuechel R; Wieland WF; Roessler W
    J Urol; 2002 Jul; 168(1):67-71. PubMed ID: 12050494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer.
    Ray ER; Chatterton K; Thomas K; Khan MS; Chandra A; O'Brien TS
    J Endourol; 2009 Jun; 23(6):983-8. PubMed ID: 19441882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
    Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
    J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors.
    Geavlete B; Multescu R; Georgescu D; Geavlete P
    J Endourol; 2009 Jun; 23(6):977-81. PubMed ID: 19473068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.
    Burger M; Stief CG; Zaak D; Stenzl A; Wieland WF; Jocham D; Otto W; Denzinger S
    Urology; 2009 Dec; 74(6):1282-6. PubMed ID: 19819538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.
    Daniltchenko DI; Riedl CR; Sachs MD; Koenig F; Daha KL; Pflueger H; Loening SA; Schnorr D
    J Urol; 2005 Dec; 174(6):2129-33, discussion 2133. PubMed ID: 16280742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy.
    Renninger M; Fahmy O; Schubert T; Schmid MA; Hassan F; Stenzl A; Gakis G
    World J Urol; 2020 Feb; 38(2):397-406. PubMed ID: 31030231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid.
    Filbeck T; Roessler W; Knuechel R; Straub M; Kiel HJ; Wieland WF
    J Endourol; 1999 Mar; 13(2):117-21. PubMed ID: 10213106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL).
    Bader MJ; Stepp H; Beyer W; Pongratz T; Sroka R; Kriegmair M; Zaak D; Welschof M; Tilki D; Stief CG; Waidelich R
    Urol Oncol; 2013 Oct; 31(7):1178-83. PubMed ID: 22440147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
    Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
    Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
    Denzinger S; Burger M; Walter B; Knuechel R; Roessler W; Wieland WF; Filbeck T
    Urology; 2007 Apr; 69(4):675-9. PubMed ID: 17445650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial.
    Gkritsios P; Hatzimouratidis K; Kazantzidis S; Dimitriadis G; Ioannidis E; Katsikas V
    Int Urol Nephrol; 2014 May; 46(5):927-33. PubMed ID: 24249423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.